CUBICIN Approved for S. aureus Bloodstream Infections in South Korea and Taiwan.
Business Wire › August 01, 2007
Linked as:
Extract
CUBICIN Approved for S. aureus Bloodstream Infections in South Korea and Taiwan.
Successful Filings, by Marketing Partners Kuhnil and TTY, Referenced Cubist's Landmark SAB/IE Phase 3 trial
LEXINGTON, Mass. -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that CUBICIN([R])(daptomycin for injection) received approvals in July for S. aureus bacteremia, including right-sided infective endocarditis (SAB/RIE), in...See the full content of this document
Sponsored links
